We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
With biotechnology employing some 268,000 people in California, industryexecutives reportedly remain optimistic about its future in the state despitea recent report indicating that biotech venture investments decreased in 2010
Noting that many of the pharmaceutical industry's best-selling products will soon lose their patent protection, industry analysts have reportedly suggested that the potential loss of nearly one-third of industry revenues in the near term could account for recent merger activity among the world's largest pharmaceutical companies
Quebec's Charest administration has reportedly launched the third of three new venture capital funds to provide more than $41 million for investment in biotechnology research
The U.K. Panel on Takeovers and Mergers has announced that it plans to amend the Takeover Code to reduce the tactical advantage that hostile offerors have under the current code, particularly when short-term investors unduly influence the outcome of hostile offers to the detriment of the offeree company and its shareholders
Sinochem Group, a China-based oil and chemicals company, has announced an agreement with Royal DSM N.V., a Dutch global life sciences and material sciences company, to form a global anti-infective joint venture to be headquartered in Hong Kong
While five venture-capital backed biotech companies have reportedly gone public in 2011, each has been forced to lower its offering price even before the initial public offering took place due to weakened demand
According to an SVP Financial Group report, contrary to conventional wisdom, biotech exits occur faster than device exits and have lower, but solid, multiples on invested capital
